PRODUCT DISCONTINUATION ANALYSIS

Identifying Systemic Discontinuation
Risks Across Gene Therapy Development

A multinational pharmaceutical company engaged Roots Analysis to assess the key clinical and commercial drivers behind discontinuation of gene therapies. Leveraging historical failure pattern analysis, the team derived actionable insights to mitigate regulatory, commercial and technological risks and strengthen its gene therapy expansion strategy

Let's Talk

The Challenge

Mitigating Investment Risk Through Insights into Gene Therapy Discontinuations

Identifying Commercial
Market Withdrawals

The client sought a granular, evidence-based understanding of commercially approved gene therapies that were withdrawn from the market, in order to decode the regulatory, commercial and strategic factors driving product failure

Interpreting Clinical Trial
Discontinuations

Limited visibility regarding terminated or suspended trials made it difficult to identify recurring challenges in gene therapy trials and distinguish high-risk assets from viable acquisition targets

Validating Investment
Viability

The client needed a data-driven framework to ensure that the potential acquisition targets possessed scalable technological platforms capable of long-term commercial success

The Roots Way

How Roots Helped?

Roots Analysis designed a structured product discontinuation analysis framework to systematically track and evaluate gene therapy program withdrawals across the industry, enabling the client to distinguish between isolated setbacks and systemic portfolio risks.

Comprehensive Discontinuation Database: The team built a proprietary database of gene therapy discontinuations by systematically tracking regulatory filings, corporate disclosures, press releases and clinical trial registries. Each discontinuation was categorized by therapeutic area, development phase, discontinuation reason and company type to enable granular analysis.

Attrition Factor Assessment: Leveraging the database, we conducted a deep-dive analysis of discontinuation drivers—including clinical attrition, commercial underperformance, strategic portfolio rationalization and regulatory setbacks—to identify patterns and early warning signals specific to gene therapy development.

Strategic Risk Mapping: The insights were translated into a portfolio risk heatmap that highlighted areas of highest discontinuation risk within the client's own pipeline. This enabled the investment committee to make data-driven decisions on resource allocation, pipeline prioritization and risk mitigation strategies.

Change We Created

Results You Can Quantify & Impact
Our Clients Can Count On

35%

Faster Risk Identification

By systematically tracking discontinuation signals across the gene therapy landscape, the client reduced the time to identify potential portfolio risks by approximately 35%, enabling earlier intervention and mitigation.

28%

Improved Capital Allocation

The portfolio risk heatmap and discontinuation insights allowed the investment committee to reallocate approximately 28% of capital from higher-risk programs to more promising opportunities with stronger clinical and commercial viability.

40%

Enhanced Strategic Confidence

With a clear, evidence-based understanding of discontinuation patterns and their drivers, the client's leadership team gained significantly greater confidence in strategic decision-making and long-term portfolio planning.